Navigation Links
Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company

SALT LAKE CITY, Feb. 24, 2011 /PRNewswire/ -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced today that it has signed agreements for manufacturing and use of trademarks with Austin, Texas-based Womens3D.

These agreements follow a product development agreement signed between the two companies in January 2011 in which they agreed to jointly develop a specialized version of TechniScan's Warm Bath Ultrasound (WBU) system specifically for Womens3D target market of women's specific health practices such as OB/GYN and general practice offices.

Under the terms of the manufacturing agreement, TechniScan will be the exclusive manufacturer and supplier of the product(s) and Womens3D will receive a license to sell the product to its target market. The license becomes exclusive upon certain conditions being met, including payment of at least $1.5 million to TechniScan in connection with the initial design and development of the product. Womens3D has also committed to purchase at least $10 million of TechniScan's products during the 36 months following FDA approval.

In addition to the manufacturing and trademark agreements, TechniScan receives shares of Womens3D common stock equal to 20 percent of the current capitalization of Womens3D.

"TechniScan is energized by our new partnership with Womens3D. We are looking forward to collaborating on the development and manufacturing of a WBU imaging system that addresses the unique needs of their target market. The partnership will potentially open new markets for our equipment and add an experienced medical imaging partner to our development efforts," said Dave Robinson, chief executive officer of TechniScan. 

Womens3D's Chief Medical Officer and Research Scientist and Imaging Director at Texas A&M's Institute for Preclinical Studies, Mark Lenox, Ph.D., conducted the technical evaluation of TechniScan's WBU system.

About TechniScanTechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's Warm Bath Ultrasound™ (WBU™) imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit

Forward Looking StatementsCertain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements. The company's future operating results are dependent upon many factors, including risk factors discussed in the company's periodic filings with the Securities and Exchange Commission, which are available for review at, including the company's Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Contact:Dave Robinson(801)

SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
(Date:10/13/2015)... MENLO PARK, Calif. , Oct. 13, 2015 ... contract of up to $100 million over five ... Infectious Diseases (NIAID), part of the National Institutes ... mitigate or treat acute or delayed effects of ... Biosciences , a division of SRI International will ...
(Date:10/13/2015)...  Nanomedical Diagnostics, a biotech company developing and ... announces the completion of a Series A financing ... --> --> ... and diagnostic platforms that empower individuals to make ... enable the company to commercially release AGILE Research, ...
(Date:10/13/2015)... Oct. 13 2015 ... "US & European markets for Meniscal Repair ... offering. --> ) has announced ... markets for Meniscal Repair - 16 Countries (2010-2021)" ... Research and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... 13, 2015 , ... NavaFit Inc. today announced the launch of its NavaFit ... participate in local fitness & sporting events, and stay motivated. Users can ... costs drive us to get more serious about fitness and wellness, individuals are constantly ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
Breaking Medicine News(10 mins):